Care Capital LLC Closes Third Fund at $300 Million.

PRINCETON, N.J. -- Care Capital LLC today announced the closing of its third life sciences venture capital fund, Care Capital Investments III LP. The fund capped investor commitments at $300 million, exceeding its original target of $225 million. Approximately 20 leading institutional investors participated as limited partners in the fund.

"We are delighted with the reception we received from the investment community," said Jan Leschly, Founder and Partner. "We are particularly gratified by the support we have received from our existing limited partners and by the strength of our new investors, with whom we look forward to developing long-term relationships. We are excited to continue our strategy of investing in later stage pre-clinical and clinical stage drug development companies."

Lazard acted as placement agent for the fund. "The success of this over-subscribed fundraising effort clearly reflects the strength and quality of the Care Capital team, its excellent investment record and its focused strategy," said Benjamin J. Sullivan, Jr., Managing Director and co-head of the Private Fund Advisory Group at Lazard.

About Care Capital LLC

Care Capital invests in life sciences companies, with a particular focus on later stage pharmaceutical and biotechnology enterprises. Jan Leschly, Argeris "Jerry" Karabelas, Richard Markham and David Ramsay, the principals of Care Capital, have many decades of experience successfully building, leading and investing in life sciences enterprises. For more information about Care Capital, please visit www.carecapital.com.